WALTHAM, Mass., May 9, 2024 /PRNewswire/ -- Syndax Pharmaceuticals (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that members of the Syndax management team will participate in a fireside chat at the Bank of America Securities 2024 Health Care Conference on Thursday, May 16, 2024, at 8:00 a.m. PT/ 11:00 a.m. ET.
A live webcast of the fireside chat can be accessed from the Investor section of the Company's website at www.syndax.com, where a replay of the event will also be available for a limited time.
About Syndax
Syndax Pharmaceuticals is a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies. Highlights of the Company's pipeline include revumenib, a highly selective menin inhibitor, and axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1 (CSF-1) receptor. For more information, please visit. For more information, please visit www.syndax.com or follow the Company on X (formerly Twitter) and LinkedIn.
Syndax Contact
Sharon Klahre
Syndax Pharmaceuticals, Inc.
This email address is being protected from spambots. You need JavaScript enabled to view it.
Tel 781.684.9827
| Last Trade: | US$13.76 |
| Daily Change: | 0.06 0.44 |
| Daily Volume: | 6,207,042 |
| Market Cap: | US$1.190B |
November 03, 2025 November 03, 2025 November 03, 2025 | |
Recursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....
CLICK TO LEARN MORE
Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MORE
